Needham & Company LLC lowered shares of Inogen (NASDAQ:INGN) from a strong-buy rating to a buy rating in a research note published on Monday morning, Marketbeat reports. The firm currently has $296.00 price objective on the medical technology company’s stock, up from their prior price objective of $254.00.

Several other research analysts have also issued reports on INGN. Zacks Investment Research upgraded shares of Inogen from a hold rating to a buy rating and set a $276.00 price target for the company in a research note on Tuesday, August 28th. Piper Jaffray Companies increased their price target on shares of Inogen to $245.00 and gave the stock an overweight rating in a research note on Tuesday, August 7th. BidaskClub lowered shares of Inogen from a strong-buy rating to a buy rating in a research note on Tuesday, July 31st. KeyCorp assumed coverage on shares of Inogen in a research note on Wednesday, June 6th. They issued an equal weight rating for the company. Finally, Stifel Nicolaus set a $258.00 price target on shares of Inogen and gave the stock a buy rating in a research note on Tuesday, August 21st. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. Inogen presently has a consensus rating of Buy and an average target price of $245.00.

Shares of NASDAQ INGN opened at $278.07 on Monday. Inogen has a 12 month low of $91.80 and a 12 month high of $287.79. The firm has a market capitalization of $5.83 billion, a price-to-earnings ratio of 212.27, a P/E/G ratio of 5.41 and a beta of 1.24.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, August 7th. The medical technology company reported $0.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.21. The company had revenue of $97.24 million during the quarter, compared to analyst estimates of $81.61 million. Inogen had a net margin of 10.39% and a return on equity of 16.51%. sell-side analysts predict that Inogen will post 2.06 earnings per share for the current fiscal year.

In other Inogen news, EVP Byron Myers sold 1,846 shares of the firm’s stock in a transaction dated Monday, June 18th. The shares were sold at an average price of $190.04, for a total transaction of $350,813.84. Following the completion of the sale, the executive vice president now directly owns 39,121 shares in the company, valued at approximately $7,434,554.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Brenton Taylor sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $184.40, for a total transaction of $922,000.00. Following the sale, the executive vice president now owns 41,576 shares of the company’s stock, valued at $7,666,614.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 103,710 shares of company stock valued at $21,855,102. 5.29% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the business. Catalyst Capital Advisors LLC bought a new stake in Inogen during the 2nd quarter valued at about $112,000. Advisors Preferred LLC bought a new stake in Inogen during the 2nd quarter valued at about $176,000. Thompson Siegel & Walmsley LLC bought a new stake in Inogen during the 2nd quarter valued at about $186,000. Raymond James Financial Services Advisors Inc. bought a new stake in Inogen during the 2nd quarter valued at about $216,000. Finally, SG Americas Securities LLC bought a new stake in Inogen during the 1st quarter valued at about $178,000. Institutional investors and hedge funds own 96.49% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Recommended Story: What are CEFs?

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.